Clinical Trials Directory

Trials / Completed

CompletedNCT00136734

Methylphenidate Treatment for Cocaine Abuse and ADHD - 1

Methylphenidate Treatment for Cocaine Abuse and ADHD

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
124 (actual)
Sponsor
New York State Psychiatric Institute · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Many cocaine dependent individuals are also diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Methylphenidate (Ritalin) is currently approved to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of methylphenidate in treating ADHD symptoms in cocaine dependent individuals.

Detailed description

Methylphenidate (MPH) is commonly used to treat individuals diagnosed with ADHD. The purpose of this study is to determine the effectiveness of MPH in treating adult cocaine dependent individuals who are also diagnosed with ADHD. Participants in this 14-week, double-blind, placebo-controlled study will be randomly assigned to receive either sustained-release MPH or placebo. All participants will receive individual cognitive behavioral therapy. The trial will last 14 weeks. It will include a 1-week placebo lead-in phase and a 2-week dose titration phase, followed by 11 weeks on a stable dose of MPH. During the titration phase, MPH will be given twice a day, starting at a dose of 10 mg/day. The dose will increase by 10 mg each day, until a final stable dose of 40 mg/day is reached. At this time, sustained-release MPH will be given as two 20 mg doses (one in the morning and one in the afternoon). Depending on a participant's tolerance of MPH, the dose will be increased to a maximum of 60 mg/day (40 mg in the morning and 20 mg in the afternoon). Participants who are unable to tolerate a dose of at least 40 mg/day of MPH will be discontinued from the study. Assessments of ADHD symptoms will be completed at weekly study visits. In addition, drug use assessments will also be completed and will include self-reports and urine toxicology tests.

Conditions

Interventions

TypeNameDescription
DRUGMethylphenidate
OTHERplaceboplacebo

Timeline

Start date
1998-04-01
Primary completion
2004-03-01
Completion
2004-03-01
First posted
2005-08-29
Last updated
2019-04-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00136734. Inclusion in this directory is not an endorsement.